We report a case of a full-term neonate with persistent pulmonary hypertension who developed asphyxia after birth and was treated with iloprost. The neonate had persistent hypoxia and did not respond to supportive treatment. Because inhaled nitric oxide (iNO) was not available in our hospital, inhaled iloprost was administered via an endotracheal tube. This resulted in an immediate elevation of oxygen saturation. Echocardiography revealed the conversion of the rightto-left ductal shunt to the left-to-right one and a decrease of the right ventricular pressure. The use of inhaled iloprost did not cause any significant side effects. Here, we describe our experience where iloprost was used in a neonate with persistent pulmonary hypertension because the standard therapy with inhaled nitric oxide was not available. (Korean J Pediatr 2009;52:1175-1180 Key Words : Persistent fetal circulation syndrome, Iloprost
Introduction
Persistent pulmonary hypertension of the newborn (PPHN) is a serious disorder with high mortality. The introduction of inhaled nitric oxide (iNO) has greatly improved survival and reduced morbidity. However, in many hospitals this form of treatment is not readily available.
Inhaled iloprost has been shown to be a safe and effective pulmonary vasodilator therapy in patients with primary pulmonary hypertension. Although few data are available about iloprost use in PPHN, it could be a rescue therapy in case of iNO unavailability or refractory to iNO therapy.
Here we describe our experience of using inhaled iloprost in a neonate with PPHN.
Case report
A 2,200 g female infant was born to a 32 year old G2P0A1 mother at 37+1 weeks gestation. Since 34 weeks of gestational age, the mother had higher blood pressure than normal but not preeclampsia. One day prior to delivery, the mother felt decreased fetal movements and an emergency Cesarean section was done because of fetal distress.
There was thick meconium staining of the amniotic fluid, central cyanosis, and no spontaneous respiratory movements. The heart rate was approximately 20-30 per minute with normal heart sounds and no murmurs. The infant was hypotonic and showed no spontaneous movements. The infant was intubated and bag and mask ventilation with cardiac massage was done. After 5 minutes, heart rate rose up to 100 per minute and respiration was done by self. The Apgar scores were 2, 5 and 7 at 1, 5 and 10 minutes respectively. There were no dysmorphic features. Both lungs were evenly aerated without crackles on auscultation. The abdomen was soft and flat without apparent organomegaly on palpation. There were two umbilical arteries and one vein.
The birth weight was 2,200 g (10-25th percentile), length 47 cm (25-50th percentile), and head circumference 32 cm (25-50th percentile).
Initial laboratory findings revealed: hemoglobin 15.6 g/dL, white blood cell (WBC) 7,300/μL, platelets 145,000/μL, normal electrolytes except aspartate aminotransferase (AST) We continued the ventilator therapy with a maximal mean airway pressure of 12 cmH2O and 100% oxygen.
The treatment included continuous administration of inotropic agents with dopamin and correction of acidosis with intravenous bicarbonate. The mean arterial blood pressure was maintained around 50 mmHg by dopamine 10 µg/min/ kg. However, the oxygen saturation was around 70-80%, and frequent dips to 50%. The oxygenation indices (mean airway pressure × FiO2/PaO2 * 100) were up to 25.
In our setting, iNO was not available, we decided to administer iloprost, having obtained informed parental consent. The baby was changed to SIMV to deliver iloprost.
Iloprost was inhalated by connecting a built-in ultrasound nebulization chamber to the inspiratory branch of the respirator circuit. While the drug was administered, the baby was not disconnected from the ventilator. Iloprost, the solution containing 20 µg in 2 mL, was inhalated with an initial dosage of 20 µg/kg/d every 90 minutes, integrating a nebulizer into the ventilatory system. After administration of inhaled iloprost, the oxygen saturation rose to 90-95% in 6-10 hours and no falls to 50%. Subsequently, the ventilation pressure and frequency could be lowered significantly (PIP 11 cmH2O, PEEP 4 cmH2O, frequency 40/min, FiO2 25%). Echocardiography showed a conversion of ductal shunt to left-to-right and concomitant decrease of the pulmonary artery pressure with systolic TR pressure gradient to 39 mmHg (Fig. 3) . Over the next 10 days, the infant continued to improve clinically and the oxygen saturation was maintained adequately up to 98% and could be weaned from the venilator therapy.
But 3 days after the weaning, the baby developed mild . But most of these interventions have not been studied in a controlled trial.
Pulmonary vasodilator therapy with iNO has been clearly
shown to improve oxygenation and decrease the need for ECMO therapy in term infants with severe PPHN [2] [3] [4] . There are several potential toxicities of iNO such as methemoglobinemia secondary to excess iNO concentrations or impaired metabolism, pulmonary injury related to increased NO2 concentrations during administration. However, iNO appears to be relatively safe when appropriately monitored 5) . The effects of iNO in PPHN have been studied extensively, so iNO is currently regarded as the mainstay of treatment and the recommended pulmonary vasodilating agent for PPHN.
Although iNO has improved outcomes for many infants with PPHN, there still remain those who do not respond.
In addition, the iNO treatment is often not available due to lack of required NO delivery systems in many hospitals.
Prostacyclin (prostaglandin I2, PGI2) is an important mediator of pulmonary vasodilation 6) . A number of studies have also shown that prostacyclin plays a role in vasodilation during the normal transition to extrauterine life 7) .
Prostacyclin is also a potent vasodilator when infused directly into the fetal lung in vivo. 8) These findings suggest that prostacyclin is another potential vasodilatory therapy in patients with PPHN.
Intravenous prostacyclin infusion is effective in reducing pulmonary arterial pressures but tends to cause systemic hypotension 9) . The half-life of prostacyclin is short because it undergoes a spontaneous hydrolysis to its stable metabolite, 6-keto-PGF1-alpha 6) . Thus, aerosolized prostacyclin has been shown to cause a selective decrease in pulmonary artery pressure 10) .
There are a few case reports on the treatment of PPHN with inhaled prostacyclin. Aerosolized prostacyclin has been administered to two neonates and improved oxygenation and reduced pulmonary pressure, without systemic hypotension 11) . And it also has had a beneficial effect on the oxygenation of a preterm neonate (28 weeks gestational age)
with respiratory distress syndrome complicated by marked hypoxemia due to PPHN 12) .
Prostacyclin enhances cyclic adenosine monophosphate . The cAMP and cGMP may compete as substrates for phosphodiesterase, enhancing the effects of NO and prostacyclin when they are used together 13) . Therefore, there is a potential synergistic effect on the pulmonary vascular tone with the combined use of these two drugs 6) . It has been shown in studies performed in experimental pulmonary hypertension in rats 14) . There are two case reports that show the beneficial effects of inhaled prostacyclin in non-responders of iNO, as well as an additive effect combining both agents 15, 16) .
Iloprost is a chemically stable prostacyclin analogue that can be delivered by nebulizers. It is stable at room temperature and has a half-life of 20-30 minutes 17) . Although the pediatric experience is limited, a study in children with pulmonary hypertension associated with congenital heart disease suggests that efficacy of inhaled iloprost is equivalent to iNO in lowering pulmonary vascular resistance 18) .
Few data are available about its use in patients with PPHN. To our knowledge, there is only one case of PPHN that has been treated with iloprost because iNO was unavailable 19) . The baby showed an improvement in oxygenation and pulmonary pressure decreased. No side effects were observed, but the baby died after 3 weeks because of other neurological problems.
This report is the first case of PPHN treated with iloprost in Korea. In our case mentioned, we used iloprost as an substitute for iNO. We believe our case is novel due to the fact that iloprost was used primarily and not in combination with iNO or other vasodilators. We chose the dosage based on literature data available 16, 19) . 
